Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $60M in Series A funding.
The round was led by RA Capital Management joined by Adjuvant Capital, Janus Henderson Investors, EN Investment, and founding investor GC Pharma.
The company intends to use the funds to continue to advance its clinical development efforts.
Led by CEO George Simeon, Curevo leverages biotechnology platform to develop vaccines. Its lead product is CRV-101, a sub-unit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults. The financing funds the 678-patient Phase 2b head-to-head trial of CRV‑101 against Shingrix® from initiation through topline data.
FinSMEs
11/02/2022